Suppliers and packagers for generic pharmaceutical drug: DABRAFENIB MESYLATE

DABRAFENIB MESYLATE

Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.

Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Novartis	TAFINLAR	dabrafenib mesylate	CAPSULE;ORAL	202806	NDA	Novartis Pharmaceuticals Corporation	0078-0681-66	120 CAPSULE in 1 BOTTLE (0078-0681-66)	2016-04-01
Novartis	TAFINLAR	dabrafenib mesylate	CAPSULE;ORAL	202806	NDA	Novartis Pharmaceuticals Corporation	0078-0682-66	120 CAPSULE in 1 BOTTLE (0078-0682-66)	2016-04-12
Novartis	TAFINLAR	dabrafenib mesylate	TABLET, FOR SUSPENSION;ORAL	217514	NDA	Novartis Pharmaceuticals Corporation	0078-1154-21	210 TABLET, FOR SUSPENSION in 1 BOTTLE (0078-1154-21)	2023-03-16

DABRAFENIB MESYLATE SUPPLIER LANDSCAPE

Last updated: February 19, 2026

This analysis details the global supplier network for Dabrafenib Mesylate, a targeted therapy for specific BRAF V600E mutation-positive cancers. It identifies key manufacturers, their production capabilities, regulatory compliance, and potential supply chain vulnerabilities. Understanding this landscape is critical for pharmaceutical companies managing R&D pipelines, manufacturing, and market access.

Who Manufactures Dabrafenib Mesylate API?

The Active Pharmaceutical Ingredient (API) for Dabrafenib Mesylate is produced by a limited number of specialized chemical manufacturers. These companies possess the advanced synthesis capabilities and stringent quality control systems required for complex pharmaceutical intermediates and APIs.

• Major API Manufacturers:

  • Novartis AG: As the originator of Tafinlar®, Novartis likely maintains significant internal API manufacturing capacity or controls key third-party suppliers through exclusive contracts. Their primary manufacturing sites are located in Switzerland and the United States. Specific production volumes are proprietary but are understood to be substantial given global demand.
  • Lonza Group AG: Lonza, a prominent contract development and manufacturing organization (CDMO), is a known supplier of complex APIs for various pharmaceutical companies. While specific contracts for Dabrafenib Mesylate are not publicly disclosed, Lonza's expertise in small molecule synthesis and its global manufacturing footprint (including sites in Switzerland, the UK, and the US) position it as a potential high-volume producer.
  • WuXi AppTec Co., Ltd.: This China-based global CDMO offers integrated R&D and manufacturing services. WuXi AppTec has a strong reputation for complex chemical synthesis and compliance with international regulatory standards. Their facilities in China are capable of large-scale API production.
  • Laurus Labs Limited: An Indian pharmaceutical company specializing in APIs and finished dosage forms. Laurus Labs has a diversified portfolio and significant API manufacturing capacity, compliant with cGMP standards. Their facilities are located in India.

• Secondary and Emerging Suppliers: The landscape may include smaller, specialized chemical companies operating as second-tier suppliers or those emerging to serve the generic market once patents expire or through licensing agreements. These entities often focus on specific synthesis steps or niche markets. Identifying these requires ongoing market intelligence.

What are the Regulatory Requirements for Dabrafenib Mesylate Production?

Production of Dabrafenib Mesylate API must adhere to rigorous global regulatory standards to ensure product quality, safety, and efficacy.

• Current Good Manufacturing Practices (cGMP): All manufacturing facilities must comply with cGMP regulations as mandated by regulatory bodies such as the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA), and other national health authorities. This includes strict control over raw materials, manufacturing processes, quality control testing, and documentation.
• Drug Master Files (DMFs): API manufacturers typically file DMFs with regulatory agencies. These confidential documents detail the chemistry, manufacturing, and controls (CMC) of the API. Pharmaceutical companies that use the API reference these DMFs in their drug product applications.
• Site Inspections: Manufacturing sites are subject to regular inspections by regulatory authorities to verify compliance. Successful inspection outcomes are critical for market authorization.
• Impurity Profiling: Comprehensive impurity profiling and control are essential. This involves identifying, quantifying, and controlling process-related impurities and degradation products to meet pharmacopeial standards and regulatory limits.
• ICH Guidelines: Compliance with International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) guidelines, particularly ICH Q7 for API manufacturing, is standard.

What is the Global Manufacturing Capacity and Scalability?

The global manufacturing capacity for Dabrafenib Mesylate API is estimated to be in the multi-metric ton range annually, driven by the demand for Tafinlar® and its potential use in combination therapies.

• Capacity Estimates: While precise figures are proprietary, major players like Novartis, Lonza, and WuXi AppTec have the infrastructure to produce hundreds of kilograms to several metric tons per year per facility. The total global capacity is likely sufficient to meet current market demand, with potential for expansion.
• Scalability Factors:
  • Synthesis Complexity: The multi-step synthesis of Dabrafenib Mesylate requires specialized equipment and expertise, which can limit rapid scaling.
  • Raw Material Sourcing: Availability and quality of key starting materials and intermediates are critical. Dependence on a single supplier for a specific intermediate can create a bottleneck.
  • Lead Times: Production campaigns for APIs are scheduled in advance, with lead times for material procurement and synthesis ranging from several months to over a year.
  • Regulatory Approval: Expanding capacity or transferring manufacturing to new sites requires regulatory notification and approval, which can add significant time to scaling efforts.
• Geographic Distribution: Major manufacturing hubs for pharmaceutical APIs, including China, India, Europe, and North America, house potential production capabilities. This geographical diversity can mitigate some supply chain risks.

What are the Key Supply Chain Risks for Dabrafenib Mesylate?

The supply chain for Dabrafenib Mesylate is subject to several risks inherent in pharmaceutical manufacturing and global trade.

• Supplier Concentration: Reliance on a small number of API manufacturers, particularly for specialized intermediates, increases vulnerability to disruptions. A single plant failure, geopolitical event, or quality issue at a key supplier could have a significant impact.
• Geopolitical Instability: Manufacturing facilities located in regions prone to political unrest, trade disputes, or natural disasters face elevated supply chain risks.
• Raw Material Volatility: Fluctuations in the availability and pricing of critical raw materials and solvents can impact production costs and timelines.
• Quality Control Failures: A single batch failure or a quality issue leading to a recall can disrupt supply and damage supplier reputation.
• Intellectual Property and Patent Landscape: While the originator's patents provide market exclusivity, future generic competition or licensing agreements can alter the supplier landscape and pricing dynamics.
• Logistics and Transportation: Global shipping delays, customs issues, and transportation costs can impact the timely delivery of APIs and intermediates.
• Environmental, Social, and Governance (ESG) Compliance: Increasingly, pharmaceutical companies scrutinize their suppliers' ESG practices. Non-compliance in areas like labor standards or environmental impact can lead to supplier de-selection.

How to Mitigate Supply Chain Risks?

Proactive risk mitigation strategies are essential for ensuring a stable and reliable supply of Dabrafenib Mesylate.

• Dual Sourcing: Establishing relationships with at least two qualified and audited API manufacturers for critical components or the final API. This requires significant investment in supplier qualification and ongoing quality agreements.
• Geographic Diversification: Sourcing from manufacturers located in different geographic regions to reduce exposure to localized risks.
• Strategic Inventory Management: Maintaining adequate safety stock of critical raw materials and finished API, balanced against shelf-life and storage costs.
• Supplier Audits and Performance Monitoring: Conducting regular, thorough audits of all suppliers and establishing key performance indicators (KPIs) to monitor quality, delivery, and compliance.
• Early Engagement with Suppliers: Involving API suppliers early in the drug development process to identify and address potential CMC challenges and ensure robust supply chain planning.
• Supply Chain Mapping: Developing a detailed understanding of the entire supply chain, including tier-2 and tier-3 suppliers, to identify hidden dependencies.
• Contingency Planning: Developing robust business continuity plans that outline responses to various disruption scenarios, including alternative sourcing options and communication protocols.
• Contractual Safeguards: Negotiating clear terms in supply agreements that address quality, delivery timelines, force majeure events, and intellectual property protection.

Key Takeaways

The Dabrafenib Mesylate API supply chain is characterized by a concentrated base of highly regulated manufacturers, with significant capacity held by established CDMOs and the originator. Key risks include supplier concentration, geopolitical factors, and raw material volatility. Mitigation strategies should focus on dual sourcing, geographic diversification, rigorous supplier oversight, and strategic inventory management.

Frequently Asked Questions

1. What is the typical lead time for sourcing Dabrafenib Mesylate API from a new supplier? The typical lead time can range from 12 to 18 months. This accounts for supplier qualification, initial batch production, quality testing, and regulatory documentation compilation (e.g., DMF update or new filing).

2. Are there any known supply shortages of Dabrafenib Mesylate API currently? Publicly available data does not indicate current widespread shortages. However, specific regional or product-line shortages can occur and are often managed through existing inventory or expedited production runs by major suppliers. Continuous market monitoring is advised.

3. What are the primary quality control parameters that generic API manufacturers must meet for Dabrafenib Mesylate? Generic API manufacturers must meet specifications outlined in approved drug master files and pharmacopeial monographs, which include assay, purity (related substances/impurities), residual solvents, particle size distribution, and polymorphism, ensuring bioequivalence to the reference product.

4. How does the patent expiry of Tafinlar® impact the Dabrafenib Mesylate API supplier landscape? Patent expiry typically opens the market to generic competition, which can lead to an increase in the number of API suppliers. This can drive down API prices but also requires careful vetting of new suppliers for quality and regulatory compliance.

5. What is the role of CDMOs in the Dabrafenib Mesylate supply chain? CDMOs play a crucial role by providing specialized manufacturing expertise, R&D support, and regulatory assistance for Dabrafenib Mesylate API. They enable pharmaceutical companies to scale production efficiently, manage complex synthesis, and meet stringent regulatory requirements without significant capital investment in internal manufacturing infrastructure.

Citations

[1] U.S. Food and Drug Administration. (n.d.). Guidance for Industry: ANDA Submissions—Refuse-to-Receive Standards. Retrieved from [FDA website]

[2] European Medicines Agency. (n.d.). Guideline on the requirements to the chemical and pharmaceutical quality of active substances. Retrieved from [EMA website]

[3] International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. (2009). ICH Harmonised Tripartite Guideline: Good Manufacturing Practice Guide for Active Pharmaceutical Ingredients Q7. Retrieved from [ICH website]

[4] Novartis AG. (Annual Reports). Form 20-F. U.S. Securities and Exchange Commission.

[5] Lonza Group AG. (Annual Reports). Financial Statements and Reports. Retrieved from [Lonza investor relations website]

[6] WuXi AppTec Co., Ltd. (Annual Reports). Financial Reports. Retrieved from [WuXi AppTec investor relations website]

[7] Laurus Labs Limited. (Annual Reports). Financial Statements and Reports. Retrieved from [Laurus Labs investor relations website]